Mucinous cystadenocarcinoma natural history: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Natural History== | ==Natural History== | ||
* Most of the mucinous cytoadenocarcinoma of ovary is confined to ovary and advanced stages of the carcinoma can have metastasis to the gastrointestinal tract. | * Most of the mucinous cytoadenocarcinoma of ovary is confined to ovary and advanced stages of the carcinoma can have metastasis to the gastrointestinal tract.<ref name="Guruprasad2012">{{cite journal|last1=Guruprasad|first1=Bhat|title=Mucinous cystadenocarcinoma of ovary: Changing treatment paradigms|journal=World Journal of Obstetrics and Gynecology|volume=1|issue=4|year=2012|pages=42|issn=2218-6220|doi=10.5317/wjog.v1.i4.42}}</ref> | ||
==Complications== | ==Complications== | ||
* Metastasis | * Metastasis | ||
Revision as of 15:18, 25 February 2016
|
Mucinous cystadenocarcinoma Microchapters |
|
Differentiating Mucinous Cystadenocarcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mucinous cystadenocarcinoma natural history On the Web |
|
American Roentgen Ray Society Images of Mucinous cystadenocarcinoma natural history |
|
Directions to Hospitals Treating Mucinous cystadenocarcinoma |
|
Risk calculators and risk factors for Mucinous cystadenocarcinoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Natural History
- Most of the mucinous cytoadenocarcinoma of ovary is confined to ovary and advanced stages of the carcinoma can have metastasis to the gastrointestinal tract.[1]
Complications
- Metastasis
Prognosis
- Advanced stages of mucinous cystadenocarcinoma have inferior prognosis.
- MCACL has a much more favorable prognosis than most other forms of adenocarcinoma and most other NSCLC's.[9][14] Cases have been documented of continued growth of these lesions over a period of 10 years without symptoms or metastasis. The overall mortality rate appears to be somewhere in the vicinity of 18% to 27%, depending on the criteria that are used to define this entity.
References
- ↑ Guruprasad, Bhat (2012). "Mucinous cystadenocarcinoma of ovary: Changing treatment paradigms". World Journal of Obstetrics and Gynecology. 1 (4): 42. doi:10.5317/wjog.v1.i4.42. ISSN 2218-6220.